Baxter International Inc.

Baxter International Inc.(BAX)股票分析

$26.130

+0.201 (+0.77%)收盘时

Loading chart…
High
26.310
Open
25.990
VWAP
26.07
Vol
3.96M
Mkt Cap
17.08B
Low
25.785
Amount
103.27M
EV/EBITDA, TTM
7.85

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others.

AI analysis of Baxter International Inc. (BAX)

hold

Baxter International Inc is currently priced at $26.13, which is near the average analyst price target of $28. The stock has a forward P/E ratio of 13.12, suggesting it may be fairly valued based on future earnings. However, the RSI is at 43.88, indicating that the stock is nearing oversold territory, which could present a buying opportunity. The main risk is the recent negative net income trend, with a significant loss of $1.12 billion reported in Q4 2025, which raises concerns about profitability moving forward.

估值指标

The current forward P/E ratio for Baxter International Inc. (BAX) is 13.12, compared to its 5-year average forward P/E of 14.08.

Forward P/E

Fair
5Y Average P/E
14.08
Current P/E
13.12
高估
17.80
低估
10.36

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
11.94
Current EV/EBITDA
7.85
高估
15.06
低估
8.83

Forward P/S

Fair
5Y Average P/S
1.53
Current P/S
1.13
高估
2.13
低估
0.94

Alphio AI Price Scenarios for BAX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%BAX

$28.00

情景价格

B

Base

Base · 50%BAX

$25.49

情景价格

B

Bear

Bear · 25%BAX

$18.18

情景价格

Whales holding BAX

E

Equity Investment Corporation

+ HoldingBAX

+10.66%

3M Return

P

Pzena Investment Management, Inc.

+ HoldingBAX

+9.97%

3M Return

G

Greenhaven Associates Inc

+ HoldingBAX

+5.94%

3M Return

T

Thompson, Siegel & Walmsley LLC

+ HoldingBAX

+3.94%

3M Return

事件时间线

2026-08-19 (ET)

08:30:00

Baxter International Appoints John Rogers as CFO

2026-08-04 (ET)

09:00:00

Baxter International Launches Cash Tender Offers Up to $500M

2026-07-30 (ET)

09:00:00

Microsoft's Strong Earnings Boosts Stock Futures Rebound

07:30:00

Company Raises Full-Year Financial Outlook to $1.91

07:30:00

Baxter Reports Q2 Revenue of $2.96B, Exceeding Expectations

资讯

BAX FAQ — answered by Alphio AI

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Baxter International Inc is currently priced at $26.13, which is near the average analyst price target of $28. The stock has a forward P/E ratio of 13.12, suggesting it may be fairly valued based on future earnings. However, the RSI is at 43.88, indicating that the stock is nearing oversold territory, which could present a buying opportunity. The main risk is the recent negative net income trend, with a significant loss of $1.12 billion reported in Q4 2025, which raises concerns about profitability moving forward.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始